1.Creaney, W, Murray, I, Healy, D. Antidepressant induced suicidal ideation. Hum Psychopharmacol 1991; 6:329–32.
2.Healy, DA. A failure to warn. Editorial. Int J Risk & Safety in Med, 1999; 12:151–6.
3.Beasley, CM, Dornseif, BE, Bosomworth, JCet al.Fluoxetine and suicide: a metaanalysis of controlled trials of treatment for depression. BMJ 1991; 303: 685–92.
4.Healy, D, Creaney, W. Antidepressant induced suicidal ideation. Brit Med J 1991; 303:1058–9.
5.Healy, D. Let them eat Prozac. James Lorimer & Co. Toronto, 2003; 269
6.Rothschild, A T, Locke, C A. Re-exposure to fluoxetine after serious suicidal attempts by three patients: the role of akathisia. J Clin Psychiat 1991; 52:491–493.
7.Teicher, M H, Glod, C, Cole, J O. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiat 1990; 147: 207–210.
8.Ayd, F. A survey of drug induced extrapyramidal reactions. JAMA 1961; 175:1054–60.
9.Lader, M. Psychiatric Disorders In: Avery's Drug Treatment, 4th Edition Eds. Speight, TM, Holford, NHG. Adis International Ltd. Auckland, New Zealand. 1987;1046–1047.
10.Wojcik, J D, Gelenberg, A J, LaBrie, R A & Mieske, M. Prevalence of tardive dyskinesia in an outpatient population. Compr Psychiat 1980; 21: 370–379.
11.Patterson, JF. Amoxapine-induced chorea. South Med J 1983; 76:1077.i
12.Joseph, A B, Wrobiewski, B A. Paradoxical akathisia caused by clonazepam, clorazepate and lorazepam in patients with traumatic encephalopathy and seizure disorders: a subtype of benzodiazepine-induced disinhibition. Behav Neurol 1993; 6: 221–3.
13.Riley, D E, Lang, A E. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology, 1993; 43:1459–1464.
14.Gerber, P E, Lynd, L D. Selective serotonin reuptake inhibitor induced movement disorders. Ann Pharmacotherap. 1998; 32: 692–8.
15.King, A, Riddle, M A, Chappell, P Bet al.Emergence of self destructive phenomena in children and adolescents during fluoxetine treatment. J Amer Acad Child Adult Psychiat 1991; 30: 176.
16Hall, W D, Mant, A, Mitchell, PBet al.Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1008–1013.
17.Jick, S S, Dean, A D, Jick, H. Antidepressants and suicide. BMJ 1995; 310: 215–8.
18.Tollefson, G D, Fawcett, J, Winokur, Get al.Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. Ann Clin Psychiat 1993; 5: 209–224.
19.Tollefson, GD, Rampey, A H, Beasley, C Met al.Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14:163–169.
20.Warshaw, MG, Keller, MB. The relationship between fluoxetine use and suicidal behaviour in 654 subjects with anxiety disorders. J Clin Psychiat 1996; 57:158–166
21.Leon, A C, Keller, M B, Warshaw, M Get al.Prospective study of fluoxetine treatment and suicidal behaviour in affectively ill subjects. Am J Psychiat 1999; 156:195–201.
22.Mackay, FJ, Dunn, NR, Wilton, LVet al.A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Safety 1997; 6: 235–246.
23.Edwards, JG. Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs 1995; 4: 141–159.
24.Kasper, S, Schindler, S, Neumeister, A. Risk of suicide in depression and its implications for psychopharmacological treatment. Int Clin Psychopharmacol 1996; 11: 71–79.
25.Committee on Safety of Medicines. Current problems in pharmacovigilance – Selective Serotonin Reuptake Inhibitors (SSRIs) 2000; 26: 11–12.
26. Food and Drug Administration, Review of antidepressants: Psycho Drugs Advisory Committee Report. September, 1991.
27.Walsh, M-T, Dinan, TG, Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiat Scand 2001; 104: 84–91.
28.Nyth, A L, Gottfries, C G. The clinical efficacy of Citalopram in the treatment of emotional disturbance in dementia disorder. Br J Psychiat 1990; 51(7): 894–901.
29.Pinner, E, Rich, CL. Effects of trazodone on aggressive behaviour in 7 patients with organic mental disorders. Am J Psychiat 1988; 145:1295–1296.
30.Stanley, B, Molcho, A, Stanley, Met al.Association of aggressive behaviour with altered serotoninergic function in patients who are not suicidal. Am J Psychiat 2000; 157:609–614.
31.Rosenbaum, JF. Clinical trials by media: the Prozac story. In (Ed. Schwartz, HI.) Psychotropic practice under fire. The influence of the Government, the media and special interests on somatic therapies. American Psychiatric Association Press, Washington, DC 1994; 3–27.
32.Khan, A, Brown, WA. Suicide rates in clinical trials of SSRIs, other antidepresants and placebo:analysis of FDA reports. Am J Psychiat 2003; 160: 790–792.
33.Hall, WD. Mant, A. Mitchell, PB. Rendle, VA, Hickie, IB. McManus, P. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1008–17.
34.Carlten, A. Waern, M. Ekedahl, A, Ranstram, J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol. Drug Safety 2001; 10: 525–530.
35.Rihmer, Z. Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur Psychiatry 2001; 16: 406–409.